Phosphate ion (gastrointestinal binding target)

Phosphate ions (PO₄³⁻) are absorbed in the gastrointestinal tract via paracellular and transcellular mechanisms. In patients with kidney disease, excessive phosphate absorption can cause hyperphosphatemia, leading to mineral and bone disorders and cardiovascular disease. Therapies called phosphate binders (such as sevelamer, calcium acetate, and lanthanum carbonate) are used to bind phosphate ions in the GI tract, forming insoluble complexes and lowering absorption. The actual molecular targets for absorption are the ions themselves; however, specific transporters (e.g., sodium-dependent phosphate transporter 2b, NaPi2b) can also be considered secondary therapeutic targets for experimental treatments. Safety concerns include gastrointestinal side effects and disruptions to normal nutrient absorption. This entity ("Phosphate ions gastrointestinal binding") is not a specific molecular target like a receptor or enzyme but rather an ionic substrate for drug action. A more canonical approach would capture "Phosphate ion (intestinal absorption target)" for structured drug target databases. If the goal is a protein/enzyme/receptor target, then "Sodium-dependent phosphate transporter 2b (NaPi2b)" or tight junction proteins (claudin/occludin) are the most relevant molecular targets.

Other names

PhosphateGastrointestinal phosphateGI phosphateIntestinal phosphate

Physical binding/sequestration of phosphate ions in the GI tract to prevent absorption; Formation of insoluble complexes excreted in feces